As DNMT3A structural studies progress and DNMT3A mutation-associated AML clinical phenotypes are studied and understood, various therapeutic strategies have been proposed for DNMT3A mutant AML, which may provide patients with more effective options to fight AML. Here, DNMT3A is linked to acute myeloid leukemia.